The probability of residual tumor detection in the second transurethral resection of pT1 urothelial bladder cancer according to the risk factors

Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 68, 394, 10.3322/caac.21492 Burger, 2013, Platinum priority – review – bladder cancer epidemiology and risk factors of urothelial bladder cancer, Eur Urol, 63, 234, 10.1016/j.eururo.2012.07.033 Sylvester, 2006, Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials, Eur Urol, 49, 466, 10.1016/j.eururo.2005.12.031 Shelley, 2001, A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer, BJU Int, 88, 209, 10.1046/j.1464-410x.2001.02306.x Cumberbatch, 2018, Repeat transurethral resection in non–muscle-invasive bladder cancer: a systematic review, Eur Urol, 73, 925, 10.1016/j.eururo.2018.02.014 Divrik, 2010, Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial, Eur Urol, 58, 185, 10.1016/j.eururo.2010.03.007 Babjuk, 2019, European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and Carcinoma In Situ) - 2019 update, Eur Urol, 76, 639, 10.1016/j.eururo.2019.08.016 Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, et al. American Urological Association (AUA)/Society of Urologic Oncology (SUO) Guideline DIAGNOSIS AND TREATMENT OF NON-MUSCLE INVASIVE BLADDER CANCER: AUA/SUO GUIDELINE 2016, Amended 2020. 2020;(May):1-45. Gontero, 2016, The impact of re-TUR on clinical outcomes in a large multi-centre cohort of T1-HG/G3 patients treated with BCG, BJU Int, 118, 44, 10.1111/bju.13354 Angulo, 2014, Second transurethral resection and prognosis of high-grade non-muscle invasive bladder cancer in patients not receiving Bacillus Calmette-Guérin, Actas Urol Esp (English Edition), 38, 164, 10.1016/j.acuro.2014.01.001 Czech, 2019, Identification of potential prognostic factors for absence of residual disease in the second resection of T1 bladder cancer, Cent Eur J Urol, 72, 252 Gill, 2014, Predictive factors for residual tumor and tumor upstaging on relook transurethral resection of bladder tumor in non-muscle invasive bladder cancer, Urol Ann, 6, 305, 10.4103/0974-7796.140990 Ayati, 2019, Second transurethral resection of bladder tumor: is it necessary in all T1 and/or high-grade tumors?, Urol J, 16, 152 Kamiya, 2017, Clinical outcomes of second transurethral resection in non-muscle invasive high-grade bladder cancer: a retrospective, multi-institutional, collaborative study, Int J Clin Oncol, 22, 353, 10.1007/s10147-016-1048-z Akitake, 2019, Predictive factors for residual cancer in second transurethral resection for non-muscle-invasive bladder cancer, Anticancer Res, 39, 4325, 10.21873/anticanres.13598 Soria, 2020, Predictive factors of the absence of residual disease at repeated transurethral resection of the bladder. Is there a possibility to avoid it in well-selected patients?, Urol Oncol, 38, 77, 10.1016/j.urolonc.2019.08.010 Giulianelli, 2017, Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience, Arch Ital Urol Androl, 89, 272, 10.4081/aiua.2017.4.272 Mori, 2020, En bloc resection for nonmuscle invasive bladder cancer: review of the recent literature, Curr Opin Urol, 30, 41, 10.1097/MOU.0000000000000697 Del Giudice, 2020, Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and its clinical impact on the management of high-risk non–muscle-invasive bladder cancer patients candidate for repeated transurethral resection, Eur Urol, 77, 101, 10.1016/j.eururo.2019.09.029